438192
Anti-LRP, Light Chain Mouse mAb (5A6)
liquid, clone 5A6, Calbiochem®
Synonyme(s) :
Anti-Low Density Lipoprotein Receptor-Related Protein
Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
About This Item
Code UNSPSC :
12352203
Nomenclature NACRES :
NA.43
Produits recommandés
Source biologique
mouse
Niveau de qualité
Forme d'anticorps
purified antibody
Type de produit anticorps
primary antibodies
Clone
5A6, monoclonal
Forme
liquid
Ne contient pas
preservative
Espèces réactives
rabbit, mouse, human
Fabricant/nom de marque
Calbiochem®
Conditions de stockage
OK to freeze
avoid repeated freeze/thaw cycles
Isotype
IgG2
Conditions d'expédition
wet ice
Température de stockage
−20°C
Modification post-traductionnelle de la cible
unmodified
Informations sur le gène
human ... LRP1(4035)
Description générale
Purified mouse monoclonal antibody. Recognizes the ~85 kDa LRP light chain protein under non-reducing conditions.
Recognizes the ~85 kDa LRP protein.
This Anti-LRP, Light Chain Mouse mAb (5A6) is validated for use in Frozen Sections, Immunoblotting, Paraffin Sections for the detection of LRP, Light Chain.
Immunogène
Human
purified, human placenta LRP
Application
Frozen Sections (1-5 µg/ml)
Immunoblotting (1-5 µg/ml)
Paraffin Sections (1-5 µg/ml, see application references)
Immunoblotting (1-5 µg/ml)
Paraffin Sections (1-5 µg/ml, see application references)
Conditionnement
Please refer to vial label for lot-specific concentration.
Avertissement
Toxicity: Standard Handling (A)
Forme physique
In 100 mM NaCl, 50 mM sodium phosphate, 1 mM EDTA, pH 6.6.
Reconstitution
Following initial thaw, aliquot and freeze (-20°C).
Autres remarques
Mikhailenko, I., et al. 2001. J. Biol. Chem.276, 39484.
Rebeck, W.G., et al. 2001. Mol. Brain Res.87, 238.
Coukos, G., et al. 1994. Am. J. Pathol.144, 383.
Daugherty, A., and Rateri, D.L. 1994. Arterioscler Thromb.14, 2017.
Strickland, D.K., et al. 1990. J. Biol. Chem.265, 17401.
Rebeck, W.G., et al. 2001. Mol. Brain Res.87, 238.
Coukos, G., et al. 1994. Am. J. Pathol.144, 383.
Daugherty, A., and Rateri, D.L. 1994. Arterioscler Thromb.14, 2017.
Strickland, D.K., et al. 1990. J. Biol. Chem.265, 17401.
Variables associated with assay conditions will dictate the proper working dilution.
Informations légales
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Vous ne trouvez pas le bon produit ?
Essayez notre Outil de sélection de produits.
Code de la classe de stockage
10 - Combustible liquids
Classe de danger pour l'eau (WGK)
WGK 1
Point d'éclair (°F)
Not applicable
Point d'éclair (°C)
Not applicable
Certificats d'analyse (COA)
Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Junling Yang et al.
Journal of molecular neuroscience : MN, 49(2), 277-288 (2012-09-05)
We previously reported that anti-amyloid-beta (Aβ) single-chain antibody (scFv59) brain delivery via recombinant adeno-associated virus (rAAV) was effective in reducing cerebral Aβ load in an Alzheimer's disease (AD) mouse model without inducing inflammation. Here, we investigated the prophylactic effects and
Abhay P Sagare et al.
The Journal of biological chemistry, 288(21), 15154-15166 (2013-04-13)
Soluble low density lipoprotein receptor-related protein-1 (sLRP1) binds ~70% of amyloid β-peptide (Aβ) in human plasma. In Alzheimer disease (AD) and individuals with mild cognitive impairment converting to AD, plasma sLRP1 levels are reduced and sLRP1 is oxidized, which results
Robert D Bell et al.
Nature cell biology, 11(2), 143-153 (2008-12-23)
Amyloid beta-peptide (Abeta) deposition in cerebral vessels contributes to cerebral amyloid angiopathy (CAA) in Alzheimer's disease (AD). Here, we report that in AD patients and two mouse models of AD, overexpression of serum response factor (SRF) and myocardin (MYOCD) in
Tomomi Kiyota et al.
Journal of neuroimmunology, 319, 80-92 (2018-03-27)
We investigated the effects of granulocyte-macrophage colony stimulating factor (GM-CSF) on behavioral and pathological outcomes in Alzheimer's disease (AD) and non-transgenic mice. GM-CSF treatment in AD mice reduced brain amyloidosis, increased plasma Aβ, and rescued cognitive impairment with increased hippocampal
Arne Herring et al.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 26(1), 117-128 (2011-09-29)
Physical activity protects brain function in healthy individuals and those with Alzheimer's disease (AD). Evidence for beneficial effects of parental exercise on the health status of their progeny is sparse and limited to nondiseased individuals. Here, we questioned whether maternal
Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..
Contacter notre Service technique